The Pharma Data

JANUARY 21, 2021

21, 2021 — U.S. President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. © 2021 HealthDay. . © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Virus RNA Research 52

The Pharma Data

JANUARY 10, 2021

11, 2021 07:11 UTC. The VIR Seek SARS-CoV-2 Solution is a comprehensive workflow for the detection of SARS-CoV-2 on environmental surfaces that includes swabbing of environmental surfaces, RNA extraction, analysis by Reverse Transcription PCR (RT-PCR) and evaluation by an advanced algorithm.

RNA 52

RNA Virus Research 52

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

JANUARY 14, 2021

14, 2021 — Multifocal microvascular injury has been observed in the brain and olfactory bulbs in postmortem observation of patients who died from COVID-19 , according to a research letter published online Dec. “Our results suggest that this may be caused by the body’s inflammatory response to the virus.”

RNA 52

RNA Virus Research 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

PLOS: DNA Science

JULY 27, 2023

The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus. emerged in late 2021. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person.

Disease 88

Disease DNA Virus RNA 88

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

PerkinElmer

JUNE 14, 2021

In October last year, remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. Remdesivir was originally developed to treat hepatitis C and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID-19. Kirschner, L.,

Virus 52

Virus RNA Vaccine Treatment 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

NOVEMBER 1, 2021

Rice University researchers have introduced an online portal to help researchers screen COVID-19 drug candidates that might attack specific proteins of the SARS-CoV-2 virus. Understanding these structures allows researchers to find binding partners that could, ideally, deactivate the virus. Computers in Biology and Medicine, 2021.

Virus 52

Virus RNA Engineering Drugs 52

The Pharma Data

JANUARY 21, 2021

22, 2021 — Everyone has heard the scary reports about the new, more infectious coronavirus variants that are circulating in countries around the world, but scientists aren’t pushing the panic button at this point. “The spike protein is needed to bind to the cell, to allow the virus to enter,” Salvatore explained.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.

DNA 86

DNA Laboratories Hospitals Virus 86

The Pharma Data

MAY 17, 2021

2 virus and the variant first identified in South Africa. Sanofi has also entered into vaccine manufacturing partnerships to help produce the Pfizer/BioNTech, Moderna and Johnson & Johnson shots ( DID , April 13 ), and it is developing a messenger RNA-based vaccine candidate with Translate Bio.

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

DECEMBER 3, 2020

Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Changes in mutationally constrained epitopes are rare, as they can cause the virus to lose its ability to infect and replicate, essentially rendering it unable to propagate itself.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

MAY 17, 2021

response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. . Pending positive outcomes of that trial and regulatory reviews, the companies anticipate their vaccine being given emergency use approval in the fourth quarter of 2021. First results are expected in the third quarter of 2021.

Immune Response 52

Immune Response Vaccine Trials RNA 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Drug Target Review

SEPTEMBER 25, 2024

2021 Oct 11 [cited 2024 Sep 4];13(20):5081. 2021 Apr [cited 2024 Sep 4];2(4):377–91. Preclinical studies in models of EGFR-mutated NSCLC, KRAS G12C-mutated NSCLC and colorectal cancer (CRC) demonstrated that TT125-802 prevents the development of resistance to EGFR inhibitors and KRAS G12C inhibitors, respectively. Cancers [Internet].

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Codon

JUNE 25, 2024

Proteins are colored blue and RNA molecules are colored orange and yellow. For a 2021 paper, researchers at the California Institute of Technology estimated how long it would take E. RNA and proteins comprise each ribosome, but the cell synthesizes these two biomolecules at different rates. Nature Microbiology (2021).

DNA 71

DNA RNA Laboratories Research 71

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

The SARS-CoV-2 virus encodes its own protease to help process a large virally-encoded polyprotein into smaller segments that it needs for its life cycle; a protease inhibitor drug can stop that from happening. The virus uses this enzyme to snip some longer viral proteins into shorter segments for use in replication. November 5, 2021.

Clinical Trials 52

Clinical Trials Virus FDA Hospitals 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. Breathe in, exhale. But now, we’re one step closer.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

MARCH 9, 2021

The study showed the antiviral activity of GSK’254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. These findings were presented today at the (virtual) 2021 Conference on Retroviruses and Opportunistic Infections (CROI).

Treatment 52

Treatment RNA Pharmacokinetics Virus 52

The Pharma Data

JUNE 26, 2021

JUNE 22 , 2021. Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 18, 2020

By the second quarter of 2021, the company plans to amend or file a new emergency use request so people who think they’re infected with COVID-19 can communicate with a medical professional online through a dedicated website to arrange a prescription and overnight delivery of the test kit. “I am hopeful that it works well.”

FDA Approval 52

FDA Approval FDA Vaccine Virus 52

The Pharma Data

MARCH 11, 2021

Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. On February 22, 2021, GSK and Sanofi announced the beginning of a new Phase 2 study with an improved antigen formulation. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

DECEMBER 31, 2020

The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. Klisyri, from Athenex, is expected to launch in the first quarter of 2021.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. billion doses by the end of 2021.

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

Codon

APRIL 9, 2023

Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. The RNA strands shut down a specific gene in the insects, and killed half after 7 days. RNA may offer a safer form of pest control in the future. The new sequences might help de-extinction efforts.

Therapies 52

Therapies RNA Engineering Vaccine 52

Codon

APRIL 2, 2023

Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). By combining this new variant with standard sequencing methods, it’s possible to identify RNA modifications in a really simple way. Nucleic Acids Research. Communications Biology.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. © 2021 HealthDay. Posted: January 2021. WEDNESDAY, Jan. vaccination efforts. 13 in the New England Journal of Medicine. .” Source link.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

DECEMBER 3, 2020

They still believe they can manufacture more than a billion doses in 2021, enough for about 500 million people. billion vaccine doses in 2021, with the 50 million shortfall for 2020 being handled as manufacturing gets going. The downgrade of this year’s 100-million-dose goal to 50 million was caused by supply-chain issues.

Vaccine 52

Vaccine Government RNA FDA 52

PLOS: DNA Science

MARCH 30, 2023

The agency launched FungiNet in 2021, as “a network for molecular surveillance and genomic epidemiology for fungal diseases,” with initial focus on C. Comparing genome sequences is important because they provide a 4-letter language in the bases A, C, G, and T (for DNA) or A, C, G, and U (for RNA).

DNA 52

DNA Hospitals Laboratories Virus 52

Codon

JUNE 11, 2024

Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. Trends in Genetics (2021). A partial solution to the problem came in 2005 when a team of researchers at the Scripps Institute found a “hacky” way to slow down the speed of nucleotides.

DNA 74

DNA Engineering RNA Small Molecule 74